FDA Approves Aducanumab for Alzheimer's Disease

 


The U.S. Food and Drug Administration (FDA) today approved aducanumab (Biogen/Eisai) to treat Alzheimer’s disease.

This is the first drug that slows Alzheimer’s disease. And, this is the beginning of a completely new future for Alzheimer’s treatments. This is a new type of Alzheimer’s treatment; it addresses the disease in a way that has never been done before, compared to currently approved drugs.

Alzheimer’s — a progressive, degenerative and fatal brain disease — is the most common cause of dementia. For Alzheimer’s Disease Facts and Figures, an annual report by the Alzhe...



For access to this article please sign in or subscribe.

 

Reader Comments(0)

 
 

Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2021